glp-1 ban Novo pressures compounders as FDA takes hold Understanding GLP-1 medications
Description
Further, our analyses show a trend towards a less frequent need of invasive phlebotomythe current mainstay treatment of the diseasein people with T2D treated with GLP-1 RAs

Gregory GA et al
For instance, some patients might benefit from a lower dose to minimize side effects, while others may need a higher dose for optimal results

Clin Hypertens
Fiber breakdown: Gut bacteria break down fiber into short-chain fatty acids (SCFAs)
